EMA Expands NaMuscla Approval for Pediatric Use and New Doses

The European Medicines Agency (EMA) has broadened the marketing authorization for NaMuscla (mexiletine), allowing its use for symptomatic treatment in children aged 6–11 and adolescents 12–17 with non-dystrophic myotonic disorders. This approval also introduces two new capsule strengths, 62 mg and 83 mg, in addition to the existing 167 mg. This expansion provides more treatment options for a younger patient population.